Please login to the form below

Not currently logged in
Email:
Password:

New head for Deallus Consulting

Claudio D’Ambrosio is to take over as CEO at life sciences consultancy

Dr-Claudio-D Ambrosio Deallus-ConsultingThe life sciences consultancy Deallus Consulting has named Claudio D'Ambrosio as its new CEO, effective September 1, 2014.

D'Ambrosio joined Deallus in 2008 to lead its oncology practice. Since 2011, has served as head of North American operations for the consultancy.

He will succeed Richard Withers, the founder and current CEO, who will remain on the board of Deallus Holdings.

“We are extremely excited about Claudio's appointment. He brings a tremendous energy and a fresh approach to how we can achieve our vision and strategic imperatives and I have no doubt he is the right person to build on the success we have achieved under Richard's leadership,” said Hunt.

D'Ambrosio added that he was delighted to have the opportunity to lead Deallus through its next phase of growth.

“This is a really exciting time for the company as we continue on our growth trajectory and strive to cement our position as leaders in life science consulting,” he said.

“The core values that are embedded in the business and the immensely talented team that have grown and shaped the organisation give me a great sense of confidence about the future.”

Deallus was founded in the UK in 2004. Today the consultancy has close to 100 employees and offices in London, New York, New Jersey, Los Angeles and Singapore.

22nd July 2014

From: Marketing

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics